Handelsbanken Fonder AB Raises Stake in Repligen Co. (NASDAQ:RGEN)

Handelsbanken Fonder AB lifted its stake in Repligen Co. (NASDAQ:RGEN) by 8.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,633 shares of the biotechnology company’s stock after purchasing an additional 1,200 shares during the period. Handelsbanken Fonder AB’s holdings in Repligen were worth $2,106,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in RGEN. Blue Trust Inc. raised its holdings in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 127 shares in the last quarter. Resources Management Corp CT ADV bought a new stake in shares of Repligen in the 3rd quarter valued at about $37,000. Quarry LP lifted its position in shares of Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 239 shares during the period. UMB Bank n.a. boosted its stake in shares of Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 110 shares in the last quarter. Finally, Global Retirement Partners LLC increased its holdings in Repligen by 54.0% during the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 129 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $161.47 on Wednesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The firm has a fifty day moving average of $155.30 and a 200 day moving average of $148.57. The firm has a market cap of $9.05 billion, a PE ratio of -316.61, a PEG ratio of 4.54 and a beta of 0.99. Repligen Co. has a one year low of $113.50 and a one year high of $203.13.

Repligen (NASDAQ:RGEN) last announced its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. As a group, research analysts predict that Repligen Co. will post 1.72 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Royal Bank of Canada increased their target price on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research report on Friday, February 21st. StockNews.com cut Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. JPMorgan Chase & Co. boosted their target price on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Canaccord Genuity Group initiated coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Finally, TD Cowen started coverage on shares of Repligen in a research report on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, five have given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Repligen has an average rating of “Moderate Buy” and an average price target of $181.00.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.